BIOBROL SYRUP

Indications

• Severe bacterial infections
• Infections caused by multidrug-resistant Gram-negative bacteria
• Pneumonia caused by Pseudomonas aeruginosa
• Complicated urinary tract infections
• Sepsis

Dosage

Children: Refer to BNF for Children for appropriate dosing guidelines tailored to the child's age, weight, and clinical condition.

Adults: Refer to specific clinical guidelines or BNF for tailored dosing recommendations based on the type and severity of the infection, as well as renal function.

Mechanism of action

Aminosididine exerts its antibacterial effects by binding to the 30S ribosomal subunit of bacteria, inhibiting protein synthesis. This binding interferes with the translation process, leading to the production of nonfunctional or toxic peptides. The antibiotic also causes misreading of mRNA, further contributing to its bactericidal activity.

Pharmacodynamics

Aminosididine demonstrates concentration-dependent bactericidal activity. Its effectiveness increases with rising concentrations, leading to a greater degree of bacterial kill. The drug primarily targets aerobic Gram-negative bacteria and some Gram-positive cocci, with a notable efficacy in treating infections caused by Pseudomonas aeruginosa. Resistance mechanisms can include enzymatic modification of the drug and changes in permeability of the bacterial cell wall.

Pharmacokinetics

Aminosididine is typically administered intravenously due to poor oral bioavailability. It has a volume of distribution that suggests good penetration into tissues, particularly in the kidney and lungs. The drug is eliminated primarily by renal excretion, and its half-life can be prolonged in patients with renal impairment. Therapeutic drug monitoring is often recommended to avoid toxicity, particularly nephrotoxicity and ototoxicity associated with aminoglycosides.

Adverse effects

• Nephrotoxicity
• Ototoxicity
• Neuromuscular blockade
• Allergic reactions
• Dizziness
• Headache

Interactions

• Increased risk of nephrotoxicity with other nephrotoxic agents
• Increased risk of ototoxicity with other ototoxic drugs
• Potential interaction with neuromuscular blocking agents

Precautions

• Renal impairment
• Hearing impairment
• Concurrent use with other ototoxic or nephrotoxic drugs
• Monitoring of renal function and hearing during treatment

Pregnancy

Use during pregnancy only if clearly needed. Risk of fetal harm cannot be ruled out.

Breast-feeding

Caution is advised. Excretion in human milk is unknown.

Storage

Store at room temperature, away from moisture and light.